I am the leader of the Lyskjær Group at the Department of Molecular Medicine (MOMA), a research group dedicated to renal cancer. Our research focuses on personalized medicine for renal cancer patient management. We aim to identify biomarkers that can improve treatment decisions and ultimately enhance survival for patients with renal cell carcinoma (RCC). We pursue this goal through comprehensive, multi-omic analyses of the tumor, its microenvironment, as well as matched blood and fecal samples.
